• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Royalty Pharma plc - Class A Ordinary Shares (NQ:RPRX)

    59.97 +1.24 (+2.11%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Jul 28, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 3,139,083
    Open 58.91
    Bid (Size) 55.88 (100)
    Ask (Size) 60.00 (100)
    Prev. Close 58.73
    Today's Range 58.91 - 60.08
    52wk Range 34.08 - 60.08
    Shares Outstanding 388,132,400
    Dividend Yield 1.57%
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    Royalty Pharma acquires royalty interest in AstraZeneca’s cliramitug for up to $425 million from Neurimmune
    From Royalty Pharma plc
    Via GlobeNewswire
    News headline image
    Royalty Pharma declares third quarter 2026 dividend
    From Royalty Pharma plc
    Via GlobeNewswire

    Performance

    YTD
    +54.3%
    +54.3%
    1 Month
    +5.0%
    +5.0%
    3 Month
    +20.8%
    +20.8%
    6 Month
    +48.2%
    +48.2%
    1 Year
    +61.8%
    +61.8%

    More News

    Read More
    News headline image
    Royalty Pharma to announce second quarter 2026 financial results on August 5, 2026
    From Royalty Pharma plc
    Via GlobeNewswire
    News headline image
    Branded Pharmaceuticals Stocks Q1 Recap: Benchmarking Royalty Pharma (NASDAQ:RPRX)
    Via StockStory
    Topics Artificial Intelligence Intellectual Property
    News headline image
    3 Unpopular Stocks We’re Skeptical Of
    Via StockStory
    Royalty Pharma (NASDAQ:RPRX) Beats Q1 Estimates and Raises Guidance, Fueling Strong Momentum ↗
    Via Chartmill
    News headline image
    Royalty Pharma (RPRX): Buy, Sell, or Hold Post Q1 Earnings?
    Via StockStory
    Topics Supply Chain
    News headline image
    Royalty Pharma to present at the Goldman Sachs 47th Annual Global Healthcare Conference
    From Royalty Pharma plc
    Via GlobeNewswire
    News headline image
    Mattel Stock Is Down 24%. Here's What a $50.9 Million Exit Could Mean ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Royalty Pharma’s Q1 Earnings Call: Our Top 5 Analyst Questions
    Via StockStory
    Topics Earnings
    News headline image
    Why One Fund’s $4 Million Centerra Gold Exit Looks Like Profit-Taking Amid a 150% Rally ↗
    Via The Motley Fool
    News headline image
    This Fund Cashed Out of Preformed Line Products Amid a 150% Stock Surge ↗
    Via The Motley Fool
    Topics Regulatory Compliance Supply Chain
    News headline image
    Royalty Pharma to present at upcoming investor conferences
    From Royalty Pharma plc
    Via GlobeNewswire
    News headline image
    Royalty Pharma (RPRX) Q1 2026 Earnings Transcript ↗
    Via The Motley Fool
    News headline image
    Royalty Pharma reports first quarter 2026 results
    From Royalty Pharma plc
    Via GlobeNewswire
    News headline image
    Royalty Pharma (RPRX) Reports Q1: Everything You Need To Know Ahead Of Earnings
    Via StockStory
    Topics Artificial Intelligence
    News headline image
    3 Unpopular Stocks We’re Skeptical Of
    Via StockStory
    News headline image
    Royalty Pharma Launches Global Translational Prize to Recognize Breakthrough Scientific Innovation
    From Royalty Pharma plc
    Via GlobeNewswire
    News headline image
    Royalty Pharma Declares Second Quarter 2026 Dividend
    From Royalty Pharma plc
    Via GlobeNewswire
    News headline image
    Royalty Pharma to Announce First Quarter 2026 Financial Results on May 6, 2026
    From Royalty Pharma plc
    Via GlobeNewswire
    News headline image
    1 Healthcare Stock with Promising Prospects and 2 Facing Headwinds
    Via StockStory
    News headline image
    Branded Pharmaceuticals Stocks Q4 Teardown: Royalty Pharma (NASDAQ:RPRX) Vs The Rest
    Via StockStory
    Topics Artificial Intelligence Intellectual Property
    News headline image
    1 Value Stock for Long-Term Investors and 2 Facing Challenges
    Via StockStory
    News headline image
    1 Cash-Producing Stock to Own for Decades and 2 That Underwhelm
    Via StockStory
    Topics Energy
    News headline image
    Royalty Pharma Announces R&D Funding Collaboration for Chronic Immune-Mediated Diseases
    From Royalty Pharma plc
    Via GlobeNewswire

    Frequently Asked Questions

    Is Royalty Pharma plc - Class A Ordinary Shares publicly traded?
    Yes, Royalty Pharma plc - Class A Ordinary Shares is publicly traded.
    What exchange does Royalty Pharma plc - Class A Ordinary Shares trade on?
    Royalty Pharma plc - Class A Ordinary Shares trades on the Nasdaq Stock Market
    What is the ticker symbol for Royalty Pharma plc - Class A Ordinary Shares?
    The ticker symbol for Royalty Pharma plc - Class A Ordinary Shares is RPRX on the Nasdaq Stock Market
    What is the current price of Royalty Pharma plc - Class A Ordinary Shares?
    The current price of Royalty Pharma plc - Class A Ordinary Shares is 59.97
    When was Royalty Pharma plc - Class A Ordinary Shares last traded?
    The last trade of Royalty Pharma plc - Class A Ordinary Shares was at 07/28/26 04:00 PM ET
    What is the market capitalization of Royalty Pharma plc - Class A Ordinary Shares?
    The market capitalization of Royalty Pharma plc - Class A Ordinary Shares is 23.28B
    How many shares of Royalty Pharma plc - Class A Ordinary Shares are outstanding?
    Royalty Pharma plc - Class A Ordinary Shares has 23B shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.